Research on online semaglutide safety identifies two concerns with products sold without a prescription: what the vial contains and what can go wrong during use. FDA advises patients to obtain a prescription and fill it at a state-licensed pharmacy. It warns against unapproved products sold to consumers under research labels.[4]
What the demonstration measured
Researchers observed 20 college students and older adults in a simulation involving gray-market peptide semaglutide. Participants could look up information online and completed an average of 15 of 34 scored tasks correctly. The researchers observed errors that could lead to incorrect doses, needle-stick injuries, or infection. The study measured performance on a checklist, not the number of people who were injured or the frequency of errors among actual buyers.[1]
What researchers found in the vials
Of six test purchases from websites selling semaglutide without a prescription, three vials arrived. None of the three pen orders arrived. The vials held about 29% to 39% more semaglutide than the labels stated. The paper reported low measured purity and described elevated bacterial endotoxin in one vial. The test results describe those three samples.[2]
How prescribed compounding fits in
The guide to pharmacy compounding and outsourcing facilities explains the oversight that applies when a drug is compounded for a prescription. Compounded drugs lack FDA approval. In a separate Novo Nordisk-funded laboratory analysis, selected compounded and follow-on products showed different impurity profiles from the originator medicines. The study did not measure adverse reactions in patients.[3][4]
FDA has also received reports of dosing errors with compounded semaglutide, including cases requiring hospitalization. Ask the dispensing pharmacist or prescriber to clarify any uncertainty about a prescribed product before using it.[4]